Community Practice Connections™: 5th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

This online education activity is designed to provide expert commentary regarding the molecular characterization of tumors and novel diagnostic techniques, focusing on hematologic malignancies and genitourinary (GU), gastrointestinal (GI), lung, and breast tumors. The most recent data on available and emerging targeted therapies in these tumor areas as well as advances in biomarkers for tumor prognostication and prediction of response to therapies are also discussed. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Illumina, Inc. and Novartis Pharmaceuticals Corporation.

Target Audience

This educational program is directed toward pathologists and oncologists interested in the management of patients with cancer. Fellows, residents, nurse practitioners, nurses, physician assistants, investigators, and other health care professionals interested in the treatment of patients with cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine testing strategies to facilitate precision diagnosis and stratify risk among patients with cancer
• Apply molecular markers to inform staging and monitoring in cancer care settings
• Discuss strategies to facilitate prognostic and predictive biomarker identification via multidisciplinary coordination between pathology and oncology departments
• Integrate tumor biomarker information in parallel with recent clinical trial evidence to personalize treatment planning in multiple lines of care
• Identify patients who might benefit from clinical trial participation based on biomarker characterization of their tumors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosures: Grant Research Support: AbbVie, Advaxis, Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Guardant Health, Merck & Co, Mirati Therapeutics, Novartis Pharmaceutical Corporation, Pfizer, Takeda Pharmaceutical Company; Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Guardant Health, Ignyta, Novartis Pharmaceutical Corporation, Pfizer, Spectrum Pharmaceuticals, Turning Point Therapeutics.

Lynette M. Sholl, MD
Professor of Pathology
Harvard Medical School
Associate Pathologist,
Brigham and Women’s Hospital
Boston, MA

Disclosures: Grant Research Support: F. Hoffmann-La Roche; Consultant: EMD Serono, AstraZeneca, Foghorn Therapeutics, Loxo Oncology; Other: Travel Support: Bristol Myers Squibb.

Yelena Y. Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: National Cancer Institute, Department of Defense, Cycle for Survival, Fred’s Team, Rgenix, Bayer Healthcare, Genentech/F. Hoffmann-La Roche, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co; Consultant: Bristol Myers Squibb, Merck, EMD Serono, Rgenix, Eli Lilly, Daiichi Sankyo, Pfizer, Bayer Healthcare, Imugene, Merck & Co, Zymeworks, Seattle Genetics, Basilea Pharmaceutica, AstraZeneca; Shareholder: Rgenix stock options.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.